$5.61
1.96%
Downside
Day's Volatility :8.18%
Upside
6.34%
24.78%
Downside
52 Weeks Volatility :63.9%
Upside
52.01%
Period | Orchestra Biomed Holdings Inc | Index (Russel 2000) |
---|---|---|
3 Months | -29.7% | 0.0% |
6 Months | -13.56% | 0.0% |
1 Year | -9.52% | 0.0% |
3 Years | -51.22% | -22.3% |
Market Capitalization | 219.0M |
Book Value | $1.23 |
Earnings Per Share (EPS) | -1.56 |
Wall Street Target Price | 15.6 |
Profit Margin | 0.0% |
Operating Margin TTM | -2166.97% |
Return On Assets TTM | -36.75% |
Return On Equity TTM | -83.22% |
Revenue TTM | 2.1M |
Revenue Per Share TTM | 0.06 |
Quarterly Revenue Growth YOY | -15.0% |
Gross Profit TTM | 0.0 |
EBITDA | -58.0M |
Diluted Eps TTM | -1.56 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.68 |
EPS Estimate Next Year | -1.76 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.4 |
What analysts predicted
Upside of 178.07%
FY20 | Y/Y Change | |
---|---|---|
Revenue | 5.7M | - |
Net Income | -21.4M | - |
Net Profit Margin | -374.45% | - |
FY21 | Y/Y Change | |
---|---|---|
Revenue | -782.0K | ↓ 113.71% |
Net Income | -23.0M | ↑ 7.77% |
Net Profit Margin | 2.9K% | ↑ 3317.42% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.5M | ↓ 551.79% |
Net Income | -33.6M | ↑ 46.03% |
Net Profit Margin | -951.26% | ↓ 3894.23% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.8M | ↓ 21.88% |
Net Income | -49.1M | ↑ 46.16% |
Net Profit Margin | -1.8K% | ↓ 828.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2M | ↑ 5.53% |
Net Income | -10.9M | ↑ 1147.83% |
Net Profit Margin | -939.86% | ↓ 860.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 915.0K | ↓ 21.39% |
Net Income | -12.0M | ↑ 10.11% |
Net Profit Margin | -1.3K% | ↓ 376.64% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 419.0K | ↓ 54.21% |
Net Income | -13.3M | ↑ 10.54% |
Net Profit Margin | -3.2K% | ↓ 1861.54% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 262.0K | ↓ 37.47% |
Net Income | -12.8M | ↓ 3.74% |
Net Profit Margin | -4.9K% | ↓ 1714.33% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 620.0K | ↑ 136.64% |
Net Income | -13.5M | ↑ 5.03% |
Net Profit Margin | -2.2K% | ↑ 2720.92% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 778.0K | ↑ 25.48% |
Net Income | -16.0M | ↑ 18.7% |
Net Profit Margin | -2.1K% | ↑ 117.47% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 38.1M | - |
Total Liabilities | 86.6M | - |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 13.5M | ↓ 64.49% |
Total Liabilities | 84.8M | ↓ 2.16% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 95.6M | ↑ 606.53% |
Total Liabilities | 43.0M | ↓ 49.22% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 95.2M | ↓ 0.38% |
Total Liabilities | 27.2M | ↓ 36.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 136.3M | ↑ 100.19% |
Total Liabilities | 36.5M | ↑ 397.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 125.9M | ↓ 7.63% |
Total Liabilities | 36.4M | ↓ 0.23% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 116.4M | ↓ 7.57% |
Total Liabilities | 36.7M | ↑ 0.71% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 95.2M | ↓ 18.17% |
Total Liabilities | 27.2M | ↓ 25.97% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 82.6M | ↓ 13.22% |
Total Liabilities | 25.4M | ↓ 6.36% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 72.4M | ↓ 12.4% |
Total Liabilities | 28.3M | ↑ 11.08% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.2M | - |
Investing Cash Flow | 27.0M | - |
Financing Cash Flow | 10.0M | - |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -19.4M | ↓ 25.8% |
Investing Cash Flow | 13.0M | ↓ 51.73% |
Financing Cash Flow | -4.0M | ↓ 139.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.4M | ↑ 64.47% |
Investing Cash Flow | 8.1M | ↑ 0.0% |
Financing Cash Flow | 56.8M | ↓ 1216.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.5M | ↓ 27.06% |
Investing Cash Flow | 8.1M | ↑ 0.0% |
Financing Cash Flow | 86.0K | ↓ 99.85% |
Sell
Neutral
Buy
Orchestra Biomed Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Orchestra Biomed Holdings Inc | -3.77% | -13.56% | -9.52% | -51.22% | -51.22% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Orchestra Biomed Holdings Inc | NA | NA | NA | -1.68 | -0.83 | -0.37 | NA | 1.23 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Orchestra Biomed Holdings Inc | Buy | $219.0M | -51.22% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Orchestra Biomed Holdings Inc
Revenue is up for the last 3 quarters, 262.0K → 778.0K (in $), with an average increase of 39.0% per quarter
Netprofit is down for the last 3 quarters, -12.81M → -15.98M (in $), with an average decrease of 11.9% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 46.6%
Organization | Orchestra Biomed Holdings Inc |
Employees | 56 |
CEO | Mr. David P. Hochman |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$5.61
-3.11%
Keyarch Acquisition Corp
$5.61
-3.11%
Connexa Sports Technologies Inc
$5.61
-3.11%
Us Value Etf
$5.61
-3.11%
First Wave Biopharma Inc
$5.61
-3.11%
Global X Msci Next Emerging
$5.61
-3.11%
Fat Projects Acquisition Corp
$5.61
-3.11%
Capital Link Global Fintech
$5.61
-3.11%
Applied Uv Inc
$5.61
-3.11%